Literature DB >> 9523086

The interaction of liposomes with the complement system.

J Szebeni1.   

Abstract

Activation of complement (C) by haptenized liposomes has been utilized for a long time to study the interaction of biological membranes with C proteins, or as a sensitive immunoassay for the measurement of specific antigens, antibodies, or serum hemolytic C levels. However, it has been increasingly recognized that regardless of antigenicity, C activation is an intrinsic property of all charged phospholipid/cholesterol bilayers. Liposome-induced C activation and its biological consequences show significant interspecies and interindividual variation, and critically depend on the properties of vesicles as well. Activation can proceed through both the classical and the alternative pathways, with or without the involvement of antibodies. The practical significance of the phenomenon is twofold: 1) opsonization of the vesicles promotes their clearance from the circulation and 2) the liberation of C3a and C5a can cause numerous, potentially adverse, biological reactions. In fact, many cardiovascular and hematological changes observed following administration of liposomes in vivo can be explained by C activation; a fact that has not yet gained wide recognition in the field of drug-carrier liposomes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9523086

Source DB:  PubMed          Journal:  Crit Rev Ther Drug Carrier Syst        ISSN: 0743-4863            Impact factor:   4.889


  24 in total

Review 1.  Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups.

Authors:  S M Moghimi; A C Hunter
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

Review 2.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

3.  Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate.

Authors:  Raul R Ribeiro; Eliane P Moura; Vitor M Pimentel; Weverton M Sampaio; Sydnei M Silva; Dante A Schettini; Cintia F Alves; Ferdinan A Melo; Wagner L Tafuri; Cynthia Demicheli; Maria N Melo; Frédéric Frézard; Marilene S M Michalick
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

Review 4.  Unintended effects of drug carriers: Big issues of small particles.

Authors:  Hamideh Parhiz; Makan Khoshnejad; Jacob W Myerson; Elizabeth Hood; Priyal N Patel; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

Review 5.  Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension.

Authors:  Ali Keshavarz; Hossam Kadry; Ahmed Alobaida; Fakhrul Ahsan
Journal:  Expert Opin Drug Deliv       Date:  2020-02-19       Impact factor: 6.648

6.  Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals.

Authors:  J Nieto; J Alvar; A B Mullen; K C Carter; C Rodríguez; M I San Andrés; M D San Andrés; A J Baillie; F González
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

7.  Materials design at the interface of nanoparticles and innate immunity.

Authors:  Gregory Lee Szeto; Erin B Lavik
Journal:  J Mater Chem B       Date:  2016-01-29       Impact factor: 6.331

8.  Dual-energy computed tomography imaging of atherosclerotic plaques in a mouse model using a liposomal-iodine nanoparticle contrast agent.

Authors:  Rohan Bhavane; Cristian Badea; Ketan B Ghaghada; Darin Clark; Deborah Vela; Anoosha Moturu; Akshaya Annapragada; G Allan Johnson; James T Willerson; Ananth Annapragada
Journal:  Circ Cardiovasc Imaging       Date:  2013-01-24       Impact factor: 7.792

Review 9.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

10.  Engineering asymmetric vesicles.

Authors:  Sophie Pautot; Barbara J Frisken; D A Weitz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.